---
title: "GEMPHARMATECH: Net profit in the first half of 2025 was 70.9055 million yuan, a year-on-year decrease of 7.12%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/254137957.md"
description: "In the first half of 2025, GEMPHARMATECH's operating revenue was 375 million yuan, a year-on-year increase of 10.11%; net profit was 70.9055 million yuan, a year-on-year decrease of 7.12%. The company plans to distribute a cash dividend of 0.3 yuan for every 10 shares based on the total share capital registered on the equity distribution registration date, totaling 12.2697 million yuan, accounting for 17.30% of the net profit"
datetime: "2025-08-22T09:51:21.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/254137957.md)
  - [en](https://longbridge.com/en/news/254137957.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/254137957.md)
---

# GEMPHARMATECH: Net profit in the first half of 2025 was 70.9055 million yuan, a year-on-year decrease of 7.12%

GEMPHARMATECH announced that in the first half of 2025, operating revenue reached 375 million yuan, a year-on-year increase of 10.11%. Net profit was 70.9055 million yuan, a year-on-year decrease of 7.12%. The company plans to distribute profits based on the total share capital registered on the equity distribution record date, deducting the shares in the company's repurchase special securities account, with a cash dividend of 0.3 yuan for every 10 shares, totaling a proposed cash dividend of 12.2697 million yuan, which accounts for 17.30% of the net profit attributable to shareholders of the listed company for the first half of 2025

### Related Stocks

- [688046.CN](https://longbridge.com/en/quote/688046.CN.md)

## Related News & Research

- [Nvidia China Optics Send Zhipu Shares Up Nearly 900% Since IPO](https://longbridge.com/en/news/286485723.md)
- [20:03 ETHarbour BioMed Announces Promising Preclinical Data for LET003, Its First AI-Enabled Drug Candidate](https://longbridge.com/en/news/286688082.md)
- [09:35 ETOpen Medicine Launches Ahead of ASCO, Introducing "Living Algorithms" for Real-Time Oncology Decision-Making](https://longbridge.com/en/news/286923155.md)
- [Lipocine Showcases Phase 3 Data for Postpartum Depression](https://longbridge.com/en/news/286923466.md)
- [09:15 ETNewport Healthcare's 2025 Outcomes Report Demonstrates Significant Improvements in Teen and Young Adult Mental Health Following Treatment](https://longbridge.com/en/news/286920260.md)